BioPharmSignal logoBioPharmSignal

Biotech News

Tango Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights

Tango Therapeutics (TNGX)Tango TherapeuticsEarnings

First clinical data from PRMT5/RAS(ON) combination trial to be pre sented in 2026 Cash position of $380 million as of March 31, 2026, with runway into 2028 beyond anticipated key data inflection points BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc.

Related news

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

RLAYRelay Therapeutics2026-07-30 20:05 EST

Relay Therapeutics to Announce Second Quarter 2026 Financial Results and Corporate Highlights on August 6, 2026

FATEFate Therapeutics2026-08-13 12:30 EST

Fate Therapeutics Reports Second Quarter 2026 Financial Results and Business Updates

COGTCogent Biosciences2026-08-10 12:00 EST

Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2026 Financial Results

LYELLyell Immunopharma2026-08-06 20:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Second Quarter 2026

RLAYRelay Therapeutics2026-08-06 20:05 EST

Relay Therapeutics Reports Second Quarter 2026 Financial Results and Corporate Updates

CMPXCompass Therapeutics2026-08-06 11:30 EST

Compass Therapeutics Reports 2026 Second Quarter Financial Results and Provides Corporate Update

CGEMCullinan Therapeutics, Inc.2026-08-06 11:00 EST

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

BMEABiomea Fusion2026-08-05 20:05 EST

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

ELVNEnliven Therapeutics2026-08-05 20:05 EST

Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update

View all latest news

Tango Therapeutics

Synthetic Lethality Oncology Company Tango Therapeutics discovers targeted cancer medicines by identifying genetic dependencies created by tumor-suppressor loss. Vopimetostat Vopimetostat is a brain-penetrant, MTA-cooperative PRMT5 inhibitor for MTAP-deleted cancers. Development includes monotherapy and combinations intended to deepen...

Recent company news

TNGXTango Therapeutics2026-08-11 11:00 EST

Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights

TNGXTango Therapeutics2026-08-06 22:24 EST

Tango Therapeutics Announces Executive Chair Transition

TNGXTango Therapeutics2026-06-22 20:05 EST

Tango Therapeutics Appoints Robert Azelby to Board of Directors

TNGXTango Therapeutics2026-06-10 02:50 EST

Tango Therapeutics Announces Pricing of $600 Million Upsized Public Offering

TNGXTango Therapeutics2026-06-08 20:01 EST

Tango Therapeutics Announces Proposed $500 Million Public Offering

Stock data

Close
23.88 USD
Market cap
3.11B USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States